Two FDA Safety Flags Not a Protocol
FDA · TGA · WADA · peer-reviewed literature Updated May 2026 Reviewed by Allmeds AI Pharmacist

CJC-1295 + Ipamorelin Dosage: Two FDA-Flagged Peptides Stacked

The CJC-1295 + ipamorelin combination is marketed online as a GH-axis stack. Both peptides are not FDA-approved, and the FDA has flagged each (CJC-1295 and ipamorelin acetate) among compounded substances that may present significant safety risks. No controlled human trial has characterised the combination dosing.

The CJC-1295 + ipamorelin combination stacks two FDA-flagged compounded peptides. Neither component is FDA-approved. No regulator-validated combination dose exists. CJC-1295 specifically has been associated with FDA-identified adverse events (increased heart rate, systemic vasodilatory reaction). Allmeds does not publish protocols.

Key Takeaways

  • Both CJC-1295 and ipamorelin acetate are on the FDA's compounded-substance significant-safety-risk position.
  • No regulator has validated the combination dose.
  • CJC-1295 specifically has been associated with FDA-identified adverse events: increased heart rate and systemic vasodilatory reaction.
  • Stimulating the GH/IGF-1 axis carries labelled risks (fluid retention, glucose intolerance, joint pain) per the FDA label for tesamorelin.
  • WADA prohibits both peptides.

Each component on the FDA position

  • CJC-1295: FDA-flagged compounded substance. FDA-identified adverse events include increased heart rate and systemic vasodilatory reaction.
  • Ipamorelin acetate: FDA-flagged compounded substance.

Combination concerns

Stacking two peptides that act on the same axis (CJC-1295 as a GHRH analogue, ipamorelin as a ghrelin-receptor agonist) does not produce a safer profile than either alone; it stacks the labelled risks of GH/IGF-1 axis stimulation (fluid retention, glucose intolerance, joint pain) and the FDA-identified CJC-1295 cardiovascular concerns. No regulator has validated the combination dose.

Check your medications before any change

Allmeds scans interactions across your full list. Free for individuals; team plans available.

Try it free → Talk to Sales

Common Questions

Why do people stack CJC-1295 and ipamorelin?

Online sources describe synergy between GHRH-analogue (CJC-1295) and ghrelin-receptor (ipamorelin) actions for greater GH pulse. Neither component is FDA-approved, and the stacking rationale has not been validated by controlled human trials.

Is the combination FDA approved?

No. Both components are FDA-flagged compounded substances. The combination has no regulator approval.

Why don't you publish a combination protocol?

Because the FDA has flagged both components and no regulator-validated dosing exists. Publishing a protocol would imply a safety floor that has not been demonstrated.

Are the cardiovascular effects of CJC-1295 a concern in the stack?

The FDA has specifically identified increased heart rate and systemic vasodilatory reaction as adverse events associated with CJC-1295. Stacking does not remove that concern.

References

  1. U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Source.
  2. U.S. Food & Drug Administration. Egrifta (tesamorelin) prescribing information. Source.
  3. World Anti-Doping Agency. WADA Prohibited List. Source.
Not medical advice. This page summarises regulator statements and peer-reviewed literature for general information. It is not a substitute for professional medical advice. Speak to your doctor or pharmacist before starting, stopping, or changing any medicine.